A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Inclusion Criteria: * Have been diagnosed with plaque psoriasis by a dermatologist * Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) * Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: * Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) * Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history